Filtri

The longevity revolution

The investment theme focusing on Aging Populations is stronger than ever. Barron’s, The Economist, Netflix, seem to agree with us. Dive into DECALIA’s expertise. Details? Just ask. More Americans Are Working Into Their 80s. What’s Keeping Them in the Workforce. As the baby boomers age, it’s becoming more common for people to remain employed into […]

Navigating through a CCC backdrop (Confusing, Contradictory & Challenging)

While China is facing structural risks from the 3Ds of Debt, Demographics and Deflation as recently coined by Morgan Stanley, the macro backdrop could be defined as CCC with economic data sending Confusing and somewhat Contradictory messages in an overall still Challenging context. Let’s take the latest US data released on Friday. Beyond the upside […]

Un futuro senza rimorsi per i viaggi in aereo

Sotto le maestose ali di un aereo si celano moltissime contraddizioni. L’eccitazione di scoprire nuove destinazioni, infatti, spesso è accompagnata dal senso di colpa per l’impronta di carbonio lasciata da questo tipo di viaggi. E se riuscissimo ad attenuare questo conflitto e a trovare un equilibrio tra il nostro desiderio di volare e quello di […]

Is this economy different?

In general, seasoned investors are wary when they hear or read somewhere that “this time is different”. Interestingly, there have been plenty of articles in the financial press lately about China turning eventually Japanese. With weakening growth and inflation already nearing 0%, the current 2nd largest world economy seems indeed on the brink of experiencing […]

IPEM 2023: DECALIA will be there!

Join us at IPEM 2023 in #paris this September!Nicolo Miscioscia, Partner and Head of Private Markets at DECALIA will join the panel “How do you run a successful emerging manager program?”.Come and meet Nicolo Miscioscia, Rafaella Ostier, Business Development and Franco Maria Facecchia, Private Markets.See you in Paris! 🚀🚀

“SELECT study, a pivotal moment for the fight against obesity”

•Novo Nordisk’s “SELECT” study released ground-breaking results last week. •The study demonstrated that Wegovy, a GLP-1 anti-obesity drug, reduces severe cardiovascular risk by 20% for non-diabetic obese patients. •This was seen as a best-case scenario, boosting confidence in Novo and Eli Lilly in particular as it paves the way for public and private payer coverage, […]

Upside Down

One of the most interesting aspects of the markets since the start of the year has been that investors have been caught completely off-guard. Your scribe included. Actually, it has been completely upside down compared to the consensus expectations and positioning that prevailed in January: underweight in equities, long China on re-opening narrative, negative techno-long […]